Guggenheim Issues Pessimistic Forecast for Billiontoone (NASDAQ:BLLN) Stock Price

Billiontoone (NASDAQ:BLLN) had its target price lowered by stock analysts at Guggenheim from $120.00 to $100.00 in a note issued to investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim’s price target points to a potential upside of 40.52% from the company’s previous close.

Several other equities analysts have also recently commented on the stock. Piper Sandler reiterated an “overweight” rating on shares of Billiontoone in a research note on Wednesday, December 10th. Zacks Research upgraded shares of Billiontoone to a “hold” rating in a research note on Tuesday, December 2nd. Wall Street Zen upgraded Billiontoone from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. William Blair assumed coverage on shares of Billiontoone in a research note on Monday, December 1st. They set an “outperform” rating on the stock. Finally, Wells Fargo & Company reduced their price objective on shares of Billiontoone from $110.00 to $90.00 and set an “equal weight” rating for the company in a report on Thursday, March 5th. Six research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Billiontoone currently has an average rating of “Moderate Buy” and an average price target of $126.71.

Billiontoone Stock Performance

Shares of NASDAQ:BLLN traded up $1.62 during midday trading on Monday, hitting $71.17. The company’s stock had a trading volume of 83,517 shares, compared to its average volume of 268,642. Billiontoone has a fifty-two week low of $61.96 and a fifty-two week high of $138.70. The company has a quick ratio of 11.32, a current ratio of 11.69 and a debt-to-equity ratio of 0.12. The firm has a market capitalization of $3.27 billion and a PE ratio of 338.89. The stock’s 50 day moving average is $80.10.

Billiontoone (NASDAQ:BLLN) last announced its earnings results on Wednesday, March 4th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.07. The business had revenue of $96.05 million for the quarter, compared to the consensus estimate of $85.85 million. The business’s revenue for the quarter was up 113.0% on a year-over-year basis.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Green Alpha Advisors LLC acquired a new stake in Billiontoone in the 4th quarter valued at about $436,000. FNY Investment Advisers LLC acquired a new position in shares of Billiontoone during the fourth quarter worth approximately $497,000. Massachusetts Financial Services Co. MA bought a new stake in shares of Billiontoone during the fourth quarter valued at approximately $13,373,000. Baillie Gifford & Co. acquired a new stake in shares of Billiontoone in the fourth quarter valued at approximately $103,786,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Billiontoone in the 4th quarter worth approximately $1,348,000.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.